These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

917 related items for PubMed ID: 22256805

  • 1. Preliminary study of two antiviral agents for hepatitis C genotype 1.
    Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C.
    N Engl J Med; 2012 Jan 19; 366(3):216-24. PubMed ID: 22256805
    [Abstract] [Full Text] [Related]

  • 2. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
    Dore GJ, Lawitz E, Hézode C, Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A, Brunetto MR, Zaltron S, Strasser SI, Weis N, Ghesquiere W, Lee SS, Larrey D, Pol S, Harley H, George J, Fung SK, de Lédinghen V, Hagens P, McPhee F, Hernandez D, Cohen D, Cooney E, Noviello S, Hughes EA.
    Gastroenterology; 2015 Feb 19; 148(2):355-366.e1. PubMed ID: 25311593
    [Abstract] [Full Text] [Related]

  • 3. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S, PROVE2 Study Team.
    N Engl J Med; 2009 Apr 30; 360(18):1839-50. PubMed ID: 19403903
    [Abstract] [Full Text] [Related]

  • 4. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
    Lok AS, Gardiner DF, Hézode C, Lawitz EJ, Bourlière M, Everson GT, Marcellin P, Rodriguez-Torres M, Pol S, Serfaty L, Eley T, Huang SP, Li J, Wind-Rotolo M, Yu F, McPhee F, Grasela DM, Pasquinelli C.
    J Hepatol; 2014 Mar 30; 60(3):490-9. PubMed ID: 24444658
    [Abstract] [Full Text] [Related]

  • 5. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
    Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S.
    World J Gastroenterol; 2016 Mar 28; 22(12):3418-31. PubMed ID: 27022224
    [Abstract] [Full Text] [Related]

  • 6. Sofosbuvir for previously untreated chronic hepatitis C infection.
    Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ.
    N Engl J Med; 2013 May 16; 368(20):1878-87. PubMed ID: 23607594
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT, Sims KD, Rodriguez-Torres M, Hézode C, Lawitz E, Bourlière M, Loustaud-Ratti V, Rustgi V, Schwartz H, Tatum H, Marcellin P, Pol S, Thuluvath PJ, Eley T, Wang X, Huang SP, McPhee F, Wind-Rotolo M, Chung E, Pasquinelli C, Grasela DM, Gardiner DF.
    Gastroenterology; 2014 Feb 16; 146(2):420-9. PubMed ID: 24184132
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
    McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ, PROVE1 Study Team.
    N Engl J Med; 2009 Apr 30; 360(18):1827-38. PubMed ID: 19403902
    [Abstract] [Full Text] [Related]

  • 13. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
    Suzuki F, Toyota J, Ikeda K, Chayama K, Mochida S, Hayashi N, Ishikawa H, Miyagoshi H, Hu W, McPhee F, Hughes EA, Kumada H.
    Antivir Ther; 2014 Apr 30; 19(5):491-9. PubMed ID: 24451122
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
    Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H.
    Hepatology; 2012 Mar 30; 55(3):742-8. PubMed ID: 21987462
    [Abstract] [Full Text] [Related]

  • 16. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1.
    Izumi N, Yokosuka O, Kawada N, Osaki Y, Yamamoto K, Sata M, Ishikawa H, Ueki T, Hu W, McPhee F, Hughes EA, Kumada H.
    Antivir Ther; 2014 Mar 30; 19(5):501-10. PubMed ID: 24451151
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT, APRICOT Study Group.
    N Engl J Med; 2004 Jul 29; 351(5):438-50. PubMed ID: 15282351
    [Abstract] [Full Text] [Related]

  • 20. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
    Berak H, Laskus T, Kołakowska-Rządzka A, Wasilewski M, Stańczak JJ, Bardadin K, Walewska-Zielecka B, Horban A.
    Adv Med Sci; 2014 Sep 29; 59(2):261-5. PubMed ID: 25117425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.